Orient Pharma Co (ROCO:4166) Owner Earnings per Share (TTM): 0.75 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4166 Orient Pharma Co Ltd ROCO:4166
70 GF Score
Price NT$24.70
GF Value NT$41.31
Valuation Significantly Undervalued
View Full Analysis

What is Orient Pharma Co Owner Earnings per Share (TTM)?

Orient Pharma Co ROCO:4166 +0.82% 70 Owner Earnings per Share (TTM) is 0.75 as of Jun. 2026. GuruFocus rates ROCO:4166 with a GF Score™ of 70/100 and a GF Value™ of NT$41.31 (Significantly Undervalued). Among 463 Drug Manufacturers companies, Orient Pharma Co ranks worse than 62.2% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Orient Pharma Co's Owner Earnings per Share (TTM) ended in Jun. 2026 was NT$0.75. It's Price-to-Owner-Earnings ratio for today is 32.93.


The historical rank and industry rank for Orient Pharma Co's Owner Earnings per Share (TTM) or its related term are showing as below:

ROCO:4166' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 22.78   Med: 35.91   Max: 112.75
Current: 32.75


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Orient Pharma Co was 112.75. The lowest was 22.78. And the median was 35.91.


ROCO:4166's Price-to-Owner-Earnings is ranked worse than
62.2% of 463 companies
in the Drug Manufacturers industry
Industry Median: 23.09 vs ROCO:4166: 32.75

Orient Pharma Co's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was NT$0.24. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.99. It's PE Ratio (TTM) ratio for today is 25.00.

Orient Pharma Co's EPS without NRI for the three months ended in Jun. 2026 was NT$0.26. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1.01. It's PE Ratio without NRI ratio for today is 24.46.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Orient Pharma Co Owner Earnings per Share (TTM) Related Terms


Orient Pharma Co Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Orient Pharma Co's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Pharma Co Owner Earnings per Share (TTM) Chart

Orient Pharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.57 -0.24 -0.75 0.42 1.06

Orient Pharma Co Quarterly Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.90 1.06 0.82 0.75

ROCO:4166 vs ZTS: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orient Pharma Co Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Orient Pharma Co's Price-to-Owner-Earnings falls into.


ROCO:4166
70GF Score
Orient Pharma Co Ltd ROCO:4166
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Pharma Co Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Orient Pharma Co's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 235
Depreciation, Depletion and Amortization 135
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 55
Change In Working Capital -137
Shares Outstanding (Diluted Average) 239

1. Start with "Net Income" from income statement. Orient Pharma Co's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was NT$235 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Orient Pharma Co's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 was NT$135 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Orient Pharma Co's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = NT$55 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Orient Pharma Co's 5-Year Average Maintenance Capital Expenditure = NT$55 Mil

5. "Change In Working Capital" is from cashflow statement. Orient Pharma Co's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-137 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Orient Pharma Co's Shares Outstanding (Diluted Average) for the months ended in Jun. 2026 was 239.333 Mil.

Orient Pharma Co's Onwer Earnings Per Share for Jun. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 235.246 +135.405+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-54.7868+-136.791)/239.333
=0.75

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=24.70/0.75
=32.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 0.75 mean?
Orient Pharma Co (ROCO:4166) has a Owner Earnings per Share (TTM) of 0.75 as of Jun. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Orient Pharma Co. According to the industry distribution chart, Orient Pharma Co ranks #288 out of 463 companies in the Drug Manufacturers industry, placing it in the top 62.2%.
Is Orient Pharma Co's Owner Earnings per Share (TTM) too high?
Orient Pharma Co's current Owner Earnings per Share (TTM) is 0.75. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.09. Orient Pharma Co's value of 0.75 is 96.8% below this industry median. Based on the distribution chart, Orient Pharma Co ranks #288 out of 463 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orient Pharma Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Owner Earnings per Share (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #288 out of 463 companies for Owner Earnings per Share (TTM). This places Orient Pharma Co in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.09. Orient Pharma Co's value of 0.75 is 96.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.09, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Owner Earnings per Share (TTM) of 0.75 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Orient Pharma Co. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Owner Earnings per Share (TTM) is 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$41.31, compared to a current price of NT$24.70 — trading 40.2% below its estimated fair value. The current Owner Earnings per Share (TTM) is 0.75 and 96.8% below the Drug Manufacturers industry median of 23.09. Orient Pharma Co's overall GF Score™ is 70/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Owner Earnings per Share (TTM) is 0.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$24.70 is trading 40.2% below its estimated GF Value™ of NT$41.31. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • Owner Earnings per Share (TTM): 0.75
  • GF Value™: NT$41.31 vs. price of NT$24.70 (40.2% below fair value)
  • GF Score™: 70/100
  • Industry Position: 96.8% below the Drug Manufacturers median (#288 of 463)

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
70GF Score

Get the complete analysis for ROCO:4166

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.70
Price
NT$41.31
GF Value